Impact of fingolimod on CD4+T cell subset and cytokine profile of relapsing remitting multiple sclerosis patients

Abstract

Fingolimod inhibits the egress of lymphocytes from lymphatic tissues and also directly affects their functions by modulation of the sphingosine-1 -phosphate receptor 1 (S1P1). Our aim was to evaluate the impact of fingolimod on diverse CD4+ T cell subsets, and cytokines. Sixty-six relapsing remitting multiple sclerosis (RAMS) patients were treated with oral fingolimod (0.5 mg) for 6 months, and blood samples were collected at baseline, 3 months, and 6 months. Serum levels of seven cytokines and five chemokines were measured by multiplex immunoassay, and frequencies of peripheral blood mononuclear cell subsets were assessed by flow cytometry, and compared with those of 60 healthy controls. CCL2 (p = 0.039), and CCL5 (p = 0.001) levels were significantly higher in fingolimod-treated patients than healthy controls, whereas end-of-study serum levels of IL-6, IL-8, IL-17A, IL-22, IL-23, TNF-alpha, CXCL10, and CXCL13 were comparable to the baseline levels. Six months of fingolimod treatment reduced CD3+ T cell (mean +/- standard deviation, 72.9% +/- 5.5 vs. 60.1% +/- 11.1, p < 0.001), CD4+ T cell (62.2% +/- 8.5 vs. 24.6% +/- 12.9, p < 0.001), CD4+CD25hi regulatory T cell (Treg) (3.4% +/- 1.3 vs. 2.0% +/- 1.4, p < 0.01), and CD19+ B cell (13.2% +/- 5.8 vs. 5.3% +/- 2.7, p < 0.001) frequencies, while CD8+ T cells (31.8% +/- 7.8 vs. 57.8% +/- 13.2, p < 0.001) were increased, and NK and NKT cells remained unchanged. the proportions of intracytoplasmic IL-4, IL-10, IFN-gamma, and TNF-alpha-producing T cells were increased, whereas IL-17-producing cells remained relatively constant as measured by flow cytometry. Fingolimod appears to primarily diminish lymphocyte subsets involved in antigen presentation (CD19+ B and CD4+ T cells) rather than immune cells (CD8+ T, NK, and NKT cells) in charge of host defense against pathogens. in contrast, a relative increase is observed in pro- and anti-inflammatory cytokine-producing T helper subsets (IFN-gamma, TNF-alpha, IL-4, and IL-10-producing CD4+ T cells), suggesting that effector T cells are suppressed to a lesser degree by S1P1 modulation.